Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253421 · ClinicalTrials.gov registry record · Phase 1
The Effects of Dopamine on Reward Processing
A Phase 1 study, sponsored by Mclean Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
NCT01253421 is a Phase 1 study that has completed, run by Mclean Hospital. The registered enrollment target is 159 participants.
The verdict
NCT01253421, a Phase 1 study, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression. Hypotheses: Administration of a single low dose of the D2/D3 antagonist amisulpride will (1) improve performance in a behavioral task assessing learning from feedback and (2) boost activation in reward-related brain regions.
Interventions
- DRUG placebo
- DRUG amisulpride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01253421
The ClinicalTrials.gov registry entry for NCT01253421 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 159 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01253421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01253421 about?
NCT01253421 is a clinical study titled "The Effects of Dopamine on Reward Processing". The purpose of this study is to evaluate the effects of a single low dose of the D2/D3 antagonist amisulpride on reward processing. More generally, this study will test the role of dopamine (a naturally occurring brain chemical) in depression. Hypotheses: Administration of a single low dose of the...
What is the current status of trial NCT01253421?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2012-02. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01253421?
The interventions under investigation include: placebo (DRUG), amisulpride (DRUG).
Who is sponsoring clinical trial NCT01253421?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.